Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia

Adoptive cell therapy utilizing ex vivo expanded polyclonal CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) is in use in clinical trials for the treatment of type 1 diabetes and prevention of graft versus host disease in bone marrow transplantation. Here, we seek to evaluate this approach in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Debalina, Biswas, Moanaro, Liao, Gongxian, Seay, Howard R, Perrin, George Q, Markusic, David M, Hoffman, Brad E, Brusko, Todd M, Terhorst, Cox, Herzog, Roland W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213815/
https://www.ncbi.nlm.nih.gov/pubmed/25364772
http://dx.doi.org/10.1038/mtm.2014.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213815/
https://www.ncbi.nlm.nih.gov/pubmed/25364772
http://dx.doi.org/10.1038/mtm.2014.30

Ejemplares similares